Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-14 6:01 pm Purchase | 2024-09-30 | 13G | ZyVersa Therapeutics, Inc. ZVSA | Anson Funds Management LP | 54,054 4.900% | 54,054 (New Position) | Filing History |
| 2024-02-14 6:09 pm Purchase | 2023-12-31 | 13G | ZyVersa Therapeutics, Inc. ZVSA | Ionic Ventures, LLC | 5,203 4.000% | 5,203 (New Position) | Filing History |
| 2024-02-14 4:12 pm Purchase | 2023-12-31 | 13G | ZyVersa Therapeutics, Inc. ZVSA | Anson Funds Management LP | 16,067 9.800% | 16,067 (New Position) | Filing History |
| 2024-02-09 4:04 pm Sale | 2023-12-31 | 13G | ZyVersa Therapeutics, Inc. ZVSA | L1 Capital Global Opportunities Master Fund, Ltd. | 0 0.000% | -5,814 (Position Closed) | Filing History |
| 2024-01-19 06:19 am Sale | 2023-12-31 | 13G | ZyVersa Therapeutics, Inc. ZVSA | INCON Co. Ltd. | 4,278 3.440% | -1,288 (-23.14%) | Filing History |
| 2023-07-18 4:01 pm Purchase | 2023-06-26 | 13G | ZyVersa Therapeutics, Inc. ZVSA | L1 Capital Global Opportunities Master Fund, Ltd. | 5,814 8.600% | 5,814 (New Position) | Filing History |
| 2023-05-12 2:58 pm Sale | 2023-04-28 | 13D | ZyVersa Therapeutics, Inc. ZVSA | Glover Stephen C. | 4,058 6.760% | -231 (-5.39%) | Filing History |
| 2023-05-12 2:55 pm Purchase | 2023-04-28 | 13D | ZyVersa Therapeutics, Inc. ZVSA | O'Connor Daniel J. | 4,492 7.700% | 40 (+0.90%) | Filing History |
| 2023-05-03 4:42 pm Purchase | 2023-04-28 | 13G | ZyVersa Therapeutics, Inc. ZVSA | Ionic Ventures, LLC | 6,019 9.990% | 6,019 (New Position) | Filing History |
| 2023-02-14 5:08 pm Unchanged | 2022-12-31 | 13G | ZyVersa Therapeutics, Inc. ZVSA | Brookfield Oaktree Holdings LLC OAK | 0 0.000% | 0 (Unchanged) | Filing History |
| 2023-02-14 4:49 pm Purchase | 2022-12-31 | 13G | ZyVersa Therapeutics, Inc. ZVSA | A.G.P. / ALLIANCE GLOBAL PARTNERS LLC | 2,427 8.900% | 2,427 (New Position) | Filing History |
| 2023-02-14 11:20 am Sale | 2022-12-31 | 13G | Larkspur Health Acquisition Corp. LSPRU | Lighthouse Investment Partners LLC | 0 0.000% | -512,176 (Position Closed) | Filing History |
| 2023-02-14 06:05 am Purchase | 2022-12-31 | 13G | ZyVersa Therapeutics, Inc. ZVSA | INCON Co. Ltd. | 5,565 16.490% | 5,565 (New Position) | Filing History |
| 2023-02-09 2:30 pm Unchanged | 2022-12-31 | 13G | ZyVersa Therapeutics, Inc. ZVSA | Hudson Bay Capital Management LP | 0 0.000% | 0 (Unchanged) | Filing History |
| 2023-01-31 09:11 am Sale | 2022-12-31 | 13G | Larkspur Health Acquisition Corp. LSPRU | Yakira Capital Management, Inc. | 0 0.000% | -512,176 (Position Closed) | Filing History |
| 2023-01-13 3:11 pm Purchase | 2023-01-13 | 13G | ZyVersa Therapeutics, Inc. ZVSA | Titcomb Shawn | 2,499 9.630% | 2,499 (New Position) | Filing History |
| 2022-12-22 5:30 pm Purchase | 2022-12-12 | 13D | ZyVersa Therapeutics, Inc. ZVSA | Glover Stephen C. | 4,289 15.100% | 4,289 (New Position) | Filing History |
| 2022-12-22 5:29 pm Purchase | 2022-12-12 | 13D | ZyVersa Therapeutics, Inc. ZVSA | O'Connor Daniel J. | 4,452 16.800% | 4,452 (New Position) | Filing History |
| 2022-03-11 09:06 am Purchase | 2022-03-03 | 13G | Larkspur Health Acquisition Corp. LSPRU | Saba Capital Management, L.P. | 474,280 6.100% | 474,280 (New Position) | Filing History |
| 2022-02-14 12:00 pm Purchase | 2021-12-31 | 13G | Larkspur Health Acquisition Corp. LSPRU | Lighthouse Investment Partners LLC | 512,176 5.280% | 512,176 (New Position) | Filing History |